Foreign companies doing business in China have focused in recent days on the case of GlaxoSmithKline, the British multinational producer of pharmaceuticals currently subject to a major investigation. Many articles to date have mainly covered the narrative of the investigation and have failed to provide an analytical approach. Instead, they are more focussed on the alleged acts and potential implications for the individuals allegedly involved than the potential exposure for the corporate entities and those corporate officers who were not directly involved in actions violating PRC law. This article aims to address the latter while also placing the case in the broader context of China today.
This article was published with the permission of Lexis Nexis.